Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas

NCT05669482 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT05669482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05669482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Lead sponsor
Verastem, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 22, 2023
Completion date
August 31, 2027
Enrollment
40 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

kras activating mutation, malignant neoplasm of pancreas, metastatic cancer, neoplasms pancreatic, pancreas cancer